GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro, David M O’Malley, Ana Oaknin, Premal Thaker, Amit M Oza, Nicoletta Colombo, David Gershenson, Carol A Aghajanian, Chel Hun Choi, Yeh Chen Lee, Mansoor Raza MirzaSee the full list of authors
7 October 2024
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomasIsabelle Ray-Coquard, Paolo Giovanni Casali, Sabrina Croce, Fiona M Fennessy, Daniela Fischerova, Robin Jones, Roberta Sanfilippo, Ignacio Zapardiel, Frédéric Amant, Jean-Yves Blay, Javier Martἰn-Broto, Antonio Casado, Sarah Chiang, Angelo Paolo Dei Tos, Rick HaasSee the full list of authors
25 September 2024
Molecular changes driving low-grade serous ovarian cancer and implications for treatmentLucy Kelliher, Roni Yoeli-Bik, Lisa Schweizer, Ernst Lengyel
30 June 2024
Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancerFong Lien Audrey Kwong, Caroline Kristunas, Clare Davenport, Jon Deeks, Sue Mallett, Ridhi Agarwal, Sean Kehoe, Dirk Timmerman, Tom Bourne, Hilary Stobart, Richard Neal, Usha Menon, Alex Gentry-Maharaj, James Brenton, Nitzan RosenfeldSee the full list of authors
13 August 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak, Robert Holloway, Dominik Denschlag, Tashanna Myers, Anna M Thijs, Kathryn P Pennington, Lucy Gilbert, Evelyn Fleming, Oleksandr Zub, Lisa M Landrum, Beyhan AtasevenSee the full list of authors
25 September 2024
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panelBhavana Pothuri, Premal Thaker, Adrienne Moore, Rosa Espinosa, Kara Medina, Deborah Collyar, Kathleen Lutz, Mihaela C Munteanu, Brian Slomovitz
13 September 2024
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE studyPremal H Thaker, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda V Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda K Golembesky
7 September 2024
Efficacy of locoregional analgesic techniques after laparotomy for gynecologic cancer: a systematic reviewLieke A Dhondt, Maya S Vereen, Ralf L O van de Laar, Robert-Jan Stolker, Maaike Dirckx, Heleen J van Beekhuizen
9 August 2024
Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic populationTejumola Olaoye, Ayushi ‐, William Boyle, Anthony Williams, Raji Ganesan, Kamana Subba, Akanksha Goyal, Elaine Leung, Rahul Chowdhary, Jennifer Pascoe, Sarah Williams, Jason Yap, Janos Balega, Satyam Kumar, Kavita SinghSee the full list of authors
11 June 2024
Sarcopenia shortens overall survival of patients with platinum-resistant recurrent ovarian cancer: inverse probability of treatment-weighting analysisMasahiro Aichi, Sho Hasegawa, Satoru Shinoda, Yukio Suzuki, Natsuko Kamiya, Yumi Ishidera, Yuichi Imai, Etsuko Miyagi, Taichi Mizushima
5 August 2024